Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 104

1.

The multifaceted role of mesenchymal stem cells in cancer.

Timaner M, Tsai KK, Shaked Y.

Semin Cancer Biol. 2019 Jun 15. pii: S1044-579X(19)30135-X. doi: 10.1016/j.semcancer.2019.06.003. [Epub ahead of print] Review.

PMID:
31212021
2.

Next Viable Routes to Targeting Pancreatic Cancer Stemness: Learning from Clinical Setbacks.

Tsai KK, Chan TS, Shaked Y.

J Clin Med. 2019 May 17;8(5). pii: E702. doi: 10.3390/jcm8050702. Review.

3.

ATF3 and JDP2 deficiency in cancer associated fibroblasts promotes tumor growth via SDF-1 transcription.

Avraham S, Korin B, Aviram S, Shechter D, Shaked Y, Aronheim A.

Oncogene. 2019 May;38(20):3812-3823. doi: 10.1038/s41388-019-0692-y. Epub 2019 Jan 22.

PMID:
30670778
4.

A new screening method for ATP-independent kinase inhibitors identifies repurposed anti-cancer drugs.

Timaner M, Shaked Y.

EBioMedicine. 2018 Nov;37:21-22. doi: 10.1016/j.ebiom.2018.10.020. Epub 2018 Oct 24. No abstract available.

5.

Correction: Dissecting the Autocrine and Paracrine Roles of the CCR2-CCL2 Axis in Tumor Survival and Angiogenesis.

Izhak L, Wildbaum G, Jung S, Stein A, Shaked Y, Karin N.

PLoS One. 2018 Apr 12;13(4):e0195170. doi: 10.1371/journal.pone.0195170. eCollection 2018.

6.

Correction: Predominant Expression of CCL2 at the Tumor Site of Prostate Cancer Patients Directs a Selective Loss of Immunological Tolerance to CCL2 That Could Be Amplified in a Beneficial Manner.

Izhak L, Wildbaum G, Weinberg U, Shaked Y, Alami J, Dumont D, Friedman B, Stein A, Karin N.

J Immunol. 2018 Apr 1;200(7):2509-2510. doi: 10.4049/jimmunol.1800167. Epub 2018 Feb 23. No abstract available.

7.

Copper oxide loaded PLGA nanospheres: towards a multifunctional nanoscale platform for ultrasound-based imaging and therapy.

Perlman O, Weitz IS, Sivan SS, Abu-Khalla H, Benguigui M, Shaked Y, Azhari H.

Nanotechnology. 2018 May 4;29(18):185102. doi: 10.1088/1361-6528/aab00c. Epub 2018 Feb 16.

PMID:
29451124
8.

Dose- and time-dependence of the host-mediated response to paclitaxel therapy: a mathematical modeling approach.

Benguigui M, Alishekevitz D, Timaner M, Shechter D, Raviv Z, Benzekry S, Shaked Y.

Oncotarget. 2017 Dec 20;9(2):2574-2590. doi: 10.18632/oncotarget.23514. eCollection 2018 Jan 5.

9.

Therapy-Educated Mesenchymal Stem Cells Enrich for Tumor-Initiating Cells.

Timaner M, Letko-Khait N, Kotsofruk R, Benguigui M, Beyar-Katz O, Rachman-Tzemah C, Raviv Z, Bronshtein T, Machluf M, Shaked Y.

Cancer Res. 2018 Mar 1;78(5):1253-1265. doi: 10.1158/0008-5472.CAN-17-1547. Epub 2018 Jan 4.

10.

CCR5 Directs the Mobilization of CD11b+Gr1+Ly6Clow Polymorphonuclear Myeloid Cells from the Bone Marrow to the Blood to Support Tumor Development.

Hawila E, Razon H, Wildbaum G, Blattner C, Sapir Y, Shaked Y, Umansky V, Karin N.

Cell Rep. 2017 Nov 21;21(8):2212-2222. doi: 10.1016/j.celrep.2017.10.104.

11.

Blocking Surgically Induced Lysyl Oxidase Activity Reduces the Risk of Lung Metastases.

Rachman-Tzemah C, Zaffryar-Eilot S, Grossman M, Ribero D, Timaner M, Mäki JM, Myllyharju J, Bertolini F, Hershkovitz D, Sagi I, Hasson P, Shaked Y.

Cell Rep. 2017 Apr 25;19(4):774-784. doi: 10.1016/j.celrep.2017.04.005.

12.

The potential clinical promise of 'multimodality' metronomic chemotherapy revealed by preclinical studies of metastatic disease.

Kerbel RS, Shaked Y.

Cancer Lett. 2017 Aug 1;400:293-304. doi: 10.1016/j.canlet.2017.02.005. Epub 2017 Feb 12. Review.

PMID:
28202353
13.

The antiangiogenic role of the pro-inflammatory cytokine interleukin-31.

Davidi S, Fremder E, Kan T, Raviv Z, Timaner M, Karin N, Hershkovitz D, Arohneim A, Shaked Y.

Oncotarget. 2017 Mar 7;8(10):16430-16444. doi: 10.18632/oncotarget.14857.

14.

Next generation metronomic chemotherapy-report from the Fifth Biennial International Metronomic and Anti-angiogenic Therapy Meeting, 6-8 May 2016, Mumbai.

Pantziarka P, Hutchinson L, André N, Benzekry S, Bertolini F, Bhattacharjee A, Chiplunkar S, Duda DG, Gota V, Gupta S, Joshi A, Kannan S, Kerbel R, Kieran M, Palazzo A, Parikh A, Pasquier E, Patil V, Prabhash K, Shaked Y, Sholler GS, Sterba J, Waxman DJ, Banavali S.

Ecancermedicalscience. 2016 Nov 2;10:689. eCollection 2016.

15.

Therapy-activated stromal cells can dictate tumor fate.

Kerbel RS, Shaked Y.

J Exp Med. 2016 Dec 12;213(13):2831-2833. Epub 2016 Nov 23. Review.

16.

Heparanase is required for activation and function of macrophages.

Gutter-Kapon L, Alishekevitz D, Shaked Y, Li JP, Aronheim A, Ilan N, Vlodavsky I.

Proc Natl Acad Sci U S A. 2016 Nov 29;113(48):E7808-E7817. Epub 2016 Nov 14.

17.

Macrophage-Induced Lymphangiogenesis and Metastasis following Paclitaxel Chemotherapy Is Regulated by VEGFR3.

Alishekevitz D, Gingis-Velitski S, Kaidar-Person O, Gutter-Kapon L, Scherer SD, Raviv Z, Merquiol E, Ben-Nun Y, Miller V, Rachman-Tzemah C, Timaner M, Mumblat Y, Ilan N, Loven D, Hershkovitz D, Satchi-Fainaro R, Blum G, Sleeman JP, Vlodavsky I, Shaked Y.

Cell Rep. 2016 Oct 25;17(5):1344-1356. doi: 10.1016/j.celrep.2016.09.083.

18.

Evidence Implicating Immunological Host Effects in the Efficacy of Metronomic Low-Dose Chemotherapy.

Shaked Y, Pham E, Hariharan S, Magidey K, Beyar-Katz O, Xu P, Man S, Wu FT, Miller V, Andrews D, Kerbel RS.

Cancer Res. 2016 Oct 15;76(20):5983-5993. Epub 2016 Aug 28.

19.

Balancing efficacy of and host immune responses to cancer therapy: the yin and yang effects.

Shaked Y.

Nat Rev Clin Oncol. 2016 Oct;13(10):611-26. doi: 10.1038/nrclinonc.2016.57. Epub 2016 Apr 26. Review.

PMID:
27118493
20.

Bortezomib-induced pro-inflammatory macrophages as a potential factor limiting anti-tumour efficacy.

Beyar-Katz O, Magidey K, Ben-Tsedek N, Alishekevitz D, Timaner M, Miller V, Lindzen M, Yarden Y, Avivi I, Shaked Y.

J Pathol. 2016 Jul;239(3):262-73. doi: 10.1002/path.4723. Epub 2016 Apr 29.

PMID:
27037906

Supplemental Content

Loading ...
Support Center